# DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award

Source: https://welltoldgrants.com/grants/ht942526alsrppcta-dow-amyotrophic-lateral-sclerosis-research-program-pilot/  
Official notice: https://www.grants.gov/search-results-detail/362195

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 2 awards worth $5.6 million in total. Applications closed on September 30, 2026.

| Field | Value |
|---|---|
| Opportunity number | HT942526ALSRPPCTA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | September 30, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 2 |
| Total funding | $5.6 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.

## Questions people ask

### Is HT942526ALSRPPCTA still open?

No. It closed on September 30, 2026. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award?

Closed September 30, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $5.6 million in total across about 2 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.